Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Fig. 3

T-PNU induced tumor control involves immune responses. a, Experimental design of RNA-sequencing of CD45+ immune cells after treatment: Four cohorts of EMT6-hHER2 tumor-bearing mice (n = 6) received following treatments: (1) untreated, (2) trastuzumab (20 mg/kg, 1x), (3) T-DM1 (15 mg/kg, 1x), and (4) T-PNU (1 mg/kg, 1x). Tumors were isolated when reached an average of 30 mm3 and CD45-positive cells were isolated with magnetic beads selection. Extracted RNA was subjected to RNA-sequencing. b, Heatmap of a customized immune-specific gene panel. c, Heatmap of an immune phenotype gene panel including adaptive and innate immune response. Asterisks denote low-responding T-PNU samples

Back to article page